// App-Quantinova.ai

5029 : STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Daniel Costin Danila

Principal Investigators

  • Jorge A. Carrasquillo

  • Kristen Rebecca Curtis

  • Daniel J. Maslyar

  • Vanessa Lemahieu

  • Bernard M. Fine

  • Michael J. Mamounas

  • Alexander Joachim Ungewickell

  • Mark R. Lackner

  • Howard I. Scher

  • Lawrence P Bellomo

  • Petrus J Hendrikx

  • Edith Szafer-Glusman

  • Amrita Herkal

  • Chintan Patel

  • Nicole A. Schreiber

  • Omar Kabbarah

  • Houston Gilbert

  • Michael J. Morris

Medical Centers

  • Genentech, Inc., South San Francisico, CA

  • Memorial Sloan Kettering Cancer Center, New York, NYGenentech, Inc., San Francisco, CAGenentech, Inc., South San Francisco, CA

  • Genentech, Inc., Redwood, CA

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Nucleoside diphosphate kinase A

  • Circulating tumor cells

  • Prostate specific antigen

  • Apparent diffusion coefficient

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved